Recent Evidences of Sepsis Treatment

Jung-Hyun Choi

doi:10.3947/ic.2008.40.2.67

Journal List > Infect Chemother > v.40(2) > 1075446

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Choi: Recent Evidences of Sepsis Treatment

Special Article

Infection and Chemotherapy

Infection and Chemotherapy 2008; 40(2): 67-75.

Published online: 20 April 2008

DOI: https://doi.org/10.3947/ic.2008.40.2.67

Recent Evidences of Sepsis Treatment

Jung-Hyun Choi, M.D.

Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Korea.

Correspondence: Jung-Hyun Choi, M.D. Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea. 665, Bupyung 6-dong, Bupyunggu, Incheon 403-720, Korea. Tel: +82-32-510-5666, 5686, Fax: +82-32-510-5683, cmcjh@catholic.ac.kr

Received 10 April 2008 Accepted 15 April 2008

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Severe sepsis and septic shock are conditions with a mortality rate about 50% despite of advances of antimicrobial treatment and supportive cares. Recently, investigators are trying to establish a scientific basis for identification of high-risk patients, or a standard practice for hemodynamic optimization and adjunctive pharmacologic therapies for these patients. Several randomized, controlled trials and meta-analyses about certain therapies showed significant reduction of mortality and morbidity. This article is a clinical review of contemporary management strategies recommended with evidences for severe sepsis and septic shock.

Keywords: Sepsis, Septic shock, Evidence-base medicine

References

1. Houck PM, Bratzler DW, Nsa W, Ma A, Barlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004. 164:637–644.

2. Ibrahim EH, Shreman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000. 118:146–155.

3. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003. 31:2742–2751.

4. Jenkins I. Evidence-based sepsis therapy: a hospitalist perspective. J Hosp Med. 2006. 1:285–295.

5. Nguyen HB, Rivers EP, Abrahamian FM, Moran GJ, Abraham E, Trzeciak S, Huang DT, Osborn T, Stevens D, Talan DA. Emergency Department Sepsis Education Program and Strategies to Improve Survival (ED-SEPSIS) Working Group. Severe sepsis and septic shock: review of the literature and emergency department management guidelines. Ann Emerg Med. 2006. 48:28–54.

6. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001. 345:1368–1377.

7. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL. International Surviving Sepsis Campaign Guidelines Committee. American Association of Critical-Care Nurses. American College of Chest Physicians. American College of Emergency Physicians. Canadian Critical Care Society. European Society of Clinical Microbiology and Infectious Diseases. European Society of Intensive Care Medicine. European Respiratory Society. International Sepsis Forum. Japanese Association for Acute Medicine. Japanese Society of Intensive Care Medicine. Society of Critical Care Medicine. Society of Hospital Medicine. Surgical Infection Society. World Federation of Societies of Intensive and Critical Care Medicine. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008. 36:296–327.

8. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000. 342:1301–1308.

9. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation. 1999. 99:2626–2632.

10. Whitcomb BW, Pradhan EK, Pittas AG, Roghmann MC, Perencevich EN. Impact of admission hyperglycemia on hospital mortality in various intensive care unit populations. Crit Care Med. 2005. 33:2772–2777.

11. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001. 345:1359–1367.

12. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006. 354:449–461.

13. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med. 1995. 23:1294–1303.

14. Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaut P, Bellissant E. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002. 288:862–871.

15. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 1998. 26:645–650.

16. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ. 2004. 329:480–488.

17. Sessler CN, Perry JC, Varney KL. Management of severe sepsis and septic shock. Curr Opin Crit Care. 2004. 20:354–363.

18. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet. 2005. 365:63–78.

19. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008. 358:111–124.

20. O'Brien JM, Ali NA, Aberegg SK, Abraham E. Sepsis. Am J Med. 2007. 120:1012–1022.

21. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001. 344:699–709.

22. Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med. 2005. 33:2266–2277.

23. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL. Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005. 353:1332–1341.

24. Laterre PF, Abraham E, Janes JM, Trzaskoma BL, Correll NL, Booth FV. ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation. Crit Care Med. 2007. 35:1457–1463.

25. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B. Researching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group. Drotrecogin alfa (activated) in children with severe sepsis: a multicenter phase III randomized controlled trial. Lancet. 2007. 369:836–843.

26. Werdan K. Immunoglobulin in sepsis: therapeutic use of immunoglobulins. Sepsis. 1999. 3:239–245.

27. Jolles S, Sewell WA, Misbah SA. Clinical use of intravenous immunoglobulin. Clin Exp Immunol. 2005. 142:1–11.

28. Pildal J, Gøtzche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis. 2004. 39:38–46.

29. Turgeon AF, Hutton B, Fergusson DA, McIntyre L, Tinmouth AA, Cameron DW, Hébert PC. Meta-analysis : intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med. 2007. 146:193–203.

30. Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med. 2007. 35:2677–2685.

31. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med. 2007. 35:2686–2692.

32. Werdan K, Pilz G, Bujdoso O, Fraunberger P, Neeser G, Schmieder RE, Viell B, Marget W, Seewald M, Walger P, Stuttmann R, Speichermann N, Peckelsen C, Kurowski V, Osterhues HH, Verner L, Neumann R, Muller-Werdan U. Score-Based Immunoglobulin Therapy of Sepsis (SBITS) Study Group. Score-based immunglobulin G therapy of patients with sepsis: The SBITS study. Crit Care Med. 2007. 35:2693–2701.

TOOLS

Similar articles